{"id":64554,"date":"2026-05-06T20:56:49","date_gmt":"2026-05-06T12:56:49","guid":{"rendered":"https:\/\/flcube.com\/?p=64554"},"modified":"2026-05-06T20:56:50","modified_gmt":"2026-05-06T12:56:50","slug":"alebund-pharmaceuticals-files-for-hong-kong-ipo-leveraging-ckd-focused-portfolio-with-commercialized-mircera-and-late-stage-hyperphosphatemia-candidates","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64554","title":{"rendered":"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates"},"content":{"rendered":"\n<p><strong>Alebund Pharmaceuticals<\/strong>, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus for an <strong>initial public offering (IPO)<\/strong> on the <strong>Hong Kong Stock Exchange<\/strong>, marking a significant milestone in its growth trajectory since founding in 2018.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-commercial-foundation\">Company Profile &amp; Commercial Foundation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Founded<\/strong><\/td><td>2018<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Chronic kidney disease (CKD) and related complications<\/td><\/tr><tr><td><strong>Commercial Product<\/strong><\/td><td>Mircera (methoxy polyethylene glycol-epoetin beta)<\/td><\/tr><tr><td><strong>Commercial Partnership<\/strong><\/td><td>Exclusive promotion rights from Roche (October 2023)<\/td><\/tr><tr><td><strong>Geographic Rights<\/strong><\/td><td>Mainland China<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Anemia associated with chronic kidney disease (CKD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Mircera, originally developed by Roche, is a long-acting erythropoietin (EPO) that provides Alebund with immediate revenue generation and established commercial infrastructure in the Chinese nephrology market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-portfolio-overview\">Pipeline Portfolio Overview<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-lead-development-candidates\">Lead Development Candidates<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Status<\/th><th>Origin<\/th><th>Mechanism\/Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>AP301<\/strong><\/td><td>Advanced development<\/td><td>Acquired from Vidasym (2021)<\/td><td>Unique phosphate binder for hyperphosphatemia (global rights)<\/td><\/tr><tr><td><strong>AP306<\/strong><\/td><td>Late-stage clinical<\/td><td>Acquired from Chugai Pharmaceutical (Japan)<\/td><td>Novel pan-phosphate transporter inhibitor for hyperphosphatemia<\/td><\/tr><tr><td><strong>AP303<\/strong><\/td><td>Preclinical<\/td><td>Internal development<\/td><td>Intended to delay or stop CKD progression<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-early-stage-pipeline\">Early-Stage Pipeline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AP308<\/strong>: Preclinical candidate<\/li>\n\n\n\n<li><strong>AP304<\/strong>: Preclinical candidate<\/li>\n\n\n\n<li><strong>AP305<\/strong>: Preclinical candidate<\/li>\n\n\n\n<li><strong>AP307<\/strong>: Preclinical candidate<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-asset-acquisition-strategy\">Strategic Asset Acquisition Strategy<\/h2>\n\n\n\n<p>Alebund has pursued a disciplined acquisition strategy to build its kidney disease portfolio:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2021<\/strong>: Secured global rights to AP301 from Vidasym, establishing a differentiated hyperphosphatemia treatment approach<\/li>\n\n\n\n<li><strong>2023<\/strong>: Partnered with Roche for exclusive Mircera promotion rights in mainland China, providing immediate commercial foundation<\/li>\n\n\n\n<li><strong>Recent<\/strong>: Acquired AP306 from Japan&#8217;s Chugai Pharmaceutical, adding a late-stage pan-phosphate transporter inhibitor to address hyperphosphatemia through a novel mechanism<\/li>\n<\/ul>\n\n\n\n<p>This strategic approach has enabled Alebund to rapidly build a comprehensive CKD-focused portfolio spanning commercial products, late-stage candidates, and early-stage innovation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-investment-rationale\">Market Opportunity &amp; Investment Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CKD Market Size<\/strong>: China has over 100 million CKD patients, representing one of the world&#8217;s largest nephrology markets<\/li>\n\n\n\n<li><strong>Hyperphosphatemia Burden<\/strong>: Affects approximately 50% of dialysis patients, with significant unmet need for improved phosphate binders<\/li>\n\n\n\n<li><strong>Commercial Validation<\/strong>: Mircera provides proven revenue stream and established relationships with nephrologists and dialysis centers<\/li>\n\n\n\n<li><strong>Pipeline Diversification<\/strong>: Multiple mechanisms targeting different aspects of CKD complications reduce development risk<\/li>\n\n\n\n<li><strong>Global Rights<\/strong>: AP301&#8217;s global rights provide international expansion opportunities beyond China<\/li>\n<\/ul>\n\n\n\n<p>The IPO filing positions Alebund to capitalize on China&#8217;s growing nephrology market while advancing its innovative pipeline addressing critical unmet needs in kidney disease management.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding IPO timing, regulatory approvals, and commercial performance. Actual outcomes may differ due to regulatory decisions, market conditions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/sehk26050403576_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26050403576_c.\"><\/object><a id=\"wp-block-file--media-79c57c3f-b873-49b0-99ea-cf7b98315038\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/sehk26050403576_c.pdf\">sehk26050403576_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/sehk26050403576_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-79c57c3f-b873-49b0-99ea-cf7b98315038\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64556,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[627,72],"class_list":["post-64554","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-alebund-pharmaceuticals","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone in its growth trajectory since founding in 2018.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64554\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates\" \/>\n<meta property=\"og:description\" content=\"Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone in its growth trajectory since founding in 2018.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64554\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T12:56:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-06T12:56:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64554#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64554\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates\",\"datePublished\":\"2026-05-06T12:56:49+00:00\",\"dateModified\":\"2026-05-06T12:56:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64554\"},\"wordCount\":414,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64554#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0603.webp\",\"keywords\":[\"Alebund Pharmaceuticals\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64554#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64554\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64554\",\"name\":\"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64554#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64554#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0603.webp\",\"datePublished\":\"2026-05-06T12:56:49+00:00\",\"dateModified\":\"2026-05-06T12:56:50+00:00\",\"description\":\"Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone in its growth trajectory since founding in 2018.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64554#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64554\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64554#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64554#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates - Insight, China&#039;s Pharmaceutical Industry","description":"Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone in its growth trajectory since founding in 2018.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64554","og_locale":"en_US","og_type":"article","og_title":"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates","og_description":"Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone in its growth trajectory since founding in 2018.","og_url":"https:\/\/flcube.com\/?p=64554","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-06T12:56:49+00:00","article_modified_time":"2026-05-06T12:56:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64554#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64554"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates","datePublished":"2026-05-06T12:56:49+00:00","dateModified":"2026-05-06T12:56:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64554"},"wordCount":414,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64554#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0603.webp","keywords":["Alebund Pharmaceuticals","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64554#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64554","url":"https:\/\/flcube.com\/?p=64554","name":"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64554#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64554#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0603.webp","datePublished":"2026-05-06T12:56:49+00:00","dateModified":"2026-05-06T12:56:50+00:00","description":"Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone in its growth trajectory since founding in 2018.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64554#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64554"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64554#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0603.webp","width":1080,"height":608,"caption":"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64554#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64554"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64554\/revisions"}],"predecessor-version":[{"id":64557,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64554\/revisions\/64557"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64556"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}